Literature DB >> 21775517

Adeno-associated virus antibody profiles in newborns, children, and adolescents.

Roberto Calcedo1, Hiroki Morizono, Lili Wang, Robert McCarter, Jianping He, David Jones, Mark L Batshaw, James M Wilson.   

Abstract

Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21775517      PMCID： PMC3165215          DOI： 10.1128/CVI.05107-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  18 in total

1.  Evidence for infection of the human embryo with adeno-associated virus in pregnancy.

Authors:  T Burguete; M Rabreau; M Fontanges-Darriet; E Roset; H D Hager; A Köppel; P Bischof; J R Schlehofer
Journal:  Hum Reprod       Date:  1999-09       Impact factor: 6.918

2.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

3.  Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors.

Authors:  Lili Wang; Roberto Calcedo; Peter Bell; Jianping Lin; Rebecca L Grant; Don L Siegel; James M Wilson
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

4.  Detection of adeno-associated virus type 2 sequences in the human genital tract.

Authors:  M Friedman-Einat; Z Grossman; F Mileguir; Z Smetana; M Ashkenazi; G Barkai; N Varsano; E Glick; E Mendelson
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

Authors:  Haiyan Jiang; Linda B Couto; Susannah Patarroyo-White; Tongyao Liu; Dea Nagy; Joseph A Vargas; Shangzhen Zhou; Ciaran D Scallan; Jurg Sommer; Sharmila Vijay; Federico Mingozzi; Katherine A High; Glenn F Pierce
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

6.  Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid.

Authors:  Luk H Vandenberghe; Lili Wang; Suryanarayan Somanathan; Yan Zhi; Joanita Figueredo; Roberto Calcedo; Julio Sanmiguel; Ravi A Desai; Christopher S Chen; Julie Johnston; Rebecca L Grant; Guangping Gao; James M Wilson
Journal:  Nat Med       Date:  2006-07-16       Impact factor: 53.440

7.  Detection of infectious adeno-associated virus particles in human cervical biopsies.

Authors:  C M Walz; T R Anisi; J R Schlehofer; L Gissmann; A Schneider; M Müller
Journal:  Virology       Date:  1998-07-20       Impact factor: 3.616

8.  Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.

Authors:  Sylvie Boutin; Virginie Monteilhet; Philippe Veron; Christian Leborgne; Olivier Benveniste; Marie Françoise Montus; Carole Masurier
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

9.  Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses.

Authors:  W P Parks; D W Boucher; J L Melnick; L H Taber; M D Yow
Journal:  Infect Immun       Date:  1970-12       Impact factor: 3.441

10.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205
View more
  117 in total

1.  Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.

Authors:  Karen Nieto; Christiane Stahl-Hennig; Barbara Leuchs; Martin Müller; Lutz Gissmann; Jürgen A Kleinschmidt
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

2.  Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.

Authors:  B Greenberg; J Butler; G M Felker; P Ponikowski; A A Voors; J M Pogoda; R Provost; J Guerrero; R J Hajjar; K M Zsebo
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

3.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 4.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

5.  Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.

Authors:  Yingyu Chen; Jocelyn A Schroeder; Erin L Kuether; Guowei Zhang; Qizhen Shi
Journal:  Mol Ther       Date:  2013-08-23       Impact factor: 11.454

6.  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.

Authors:  Lluis Samaranch; Ernesto A Salegio; Waldy San Sebastian; Adrian P Kells; Kevin D Foust; John R Bringas; Clementine Lamarre; John Forsayeth; Brian K Kaspar; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-03-28       Impact factor: 5.695

7.  A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise.

Authors:  Yewande Pearse; Michelina Iacovino
Journal:  Med Res Arch       Date:  2020-02-21

8.  Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Authors:  Subhashini Jagu; Balusubramanyam Karanam; Joshua W Wang; Hatem Zayed; Margit Weghofer; Sarah A Brendle; Karla K Balogh; Kerstin Pino Tossi; Richard B S Roden; Neil D Christensen
Journal:  Vaccine       Date:  2015-09-15       Impact factor: 3.641

9.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

Review 10.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.